Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004002 · ClinicalTrials.gov registry record · Phase 1
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Study locations
NCT00004002 is a Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by NYU Langone Health. The trial reports 5 study locations across 2 states.
The verdict
NCT00004002, a Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid tumors or lymphoma that have not responded to previous treatment.
Conditions Studied
Interventions
- DRUG bortezomib
Study Locations (5)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004002
The ClinicalTrials.gov registry entry for NCT00004002 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.
NCT00004002 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00004002 about?
NCT00004002 is a clinical study titled "PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid tumors or lymphoma that have not responded to previous treatment.
What is the current status of trial NCT00004002?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07.
What conditions does trial NCT00004002 study?
This clinical trial studies the following conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Small Intestine Cancer.
What interventions are being tested in trial NCT00004002?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00004002?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004002 being conducted?
This trial has 5 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Lymphoma
All registered trials for this condition
Unspecified Adult Solid Tumor, Protocol Specific
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.